AIM ImmunoTech is trading 7.83% up at $0.26 in after-hours trading after the broader biotech sector rallied on positive Moderna personalized cancer-vaccine results.
- No major company-specific announcement dated August 19, 2026 was identified.
- Latest company press-release coverage centers on its August 10 quarterly results and operational update.
- The move therefore appears sector-led rather than driven by a new company catalyst.